India Active Pharmaceutical Ingredients Market report covers the present scenario and the growth prospects of the API market in India during the period 2014-2019. To calculate the market size, the report considers the revenue generated from the sales of API by vendors in the market. The report provides the vendor landscape and a corresponding detailed analysis of the top three vendors in the market. The market segmentation data and analysis is also provided for the following segmentation types: type of production process and area of therapy.
Analysts forecast the Active Pharmaceutical Ingredients market in India to grow at a CAGR of 10.76 percent over the period 2014-2019.
In addition, the report discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.
API Market in India 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts.
The report recognizes the following companies as the key players in the API Market in India: Aurobindo Pharma Ltd., Cipla Ltd. and Dr. Reddy's Laboratories Ltd.
Other Prominent Vendors in the market are: Anuh Pharma, Alembic Pharmaceuticals, A. R. Life Sciences, Atul Bioscience, Biocon, Cadila Pharmaceuticals, Calyx Chemicals & Pharmaceuticals, CIRON Drugs and Pharmaceuticals, CTX Life Sciences, Dishman Pharmaceuticals & Chemicals, Elder Pharmaceuticals, Emcure Pharmaceuticals, FDC, Glenmark Pharmaceuticals, Hetero Drugs, Hikal, Ind-Swift Laboratories, Ipca Laboratories, J. B. Chemicals and Pharmaceuticals, Laurus Labs, Lupin, Mangalam Drugs & Organics, Mylan Laboratories, Orchid Chemicals and Pharmaceuticals, Ranbaxy Laboratories, Sandoz, Sequent Scientific, Shasun Pharmaceuticals, Sterling Biotech, Sun Pharmaceutical Industries, The Piramal Group, Torrent Pharmaceuticals, Unichem Laboratories and Wockhardt.
One major trend emerging in this market is the strong focus on the development and introduction of high-potency API. Such products are increasingly used in oncology and for the provision of targeted therapy.
According to the report, one of the key drivers contributing to the growth of the API market in India is the increased outsourcing of API by global pharmaceutical companies to low-cost vendors in India. This is done to reduce both manufacturing and infrastructure costs.
Further, the report states that stringent regulations are one of the major challenges that the market faces. Such regulations are particularly well defined for the export of products to developed regions such as Western Europe and North America. Vendors are required to comply with elaborate procedures prior to product commercialization.
Have any Query on the Report get your Queries Resolved at http://www.sandlerresearch.org/inquire-before-buying?rname=29727 .
(Prices start at US $2500 for a single user PDF)